Trial Profile

A Phase I/IIa, Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer's Disease

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Jul 2025 According to a NKGen Biotech media release, the data from this study were presented at the Alzheimer's Association International Conference 2025 (AAIC 2025) held in Toronto, Canada and online from July 27-31, 2025.
23 Jun 2025 According to a NKGen Biotech media release, the company announced the activation of two additional clinical trial sites. The newly activated sites, Ottawa Memory Clinic in Canada and AdventHealth Orlando in Florida, USA, are now open for patient enrollment, broadening access and accelerating recruitment for the trial.
23 Jun 2025 According to a NKGen Biotech media release, the company has received clearance from Health Canada for its Clinical Trial Application (CTA).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com